Właściwości katalityczne i biomedyczne związków zawierających jony rutenu (II) oraz Rutenu (III)

Ruthenium complexes appear in scientific publications mainly as catalysts in the olefins metathesis process. In this review, we want to indicate the research niche regarding the use of ruthenium(II) and ruthenium(III) complexes in other catalytic processes, i.e. polymerization or epoxidation of olefins and depolymerization. We would like to combine the catalytic properties of ruthenium(II,III) complex compounds with their biomedical activity due to the growing problem of drug resistance (including antibiotic resistance). Scientists have been designing new metallopharmaceuticals exhibiting biological activity for several years, therefore this requires a critical review of the literature. The main goal of designing new metallodrugs is to create compounds with new or stronger biological properties compared to free ligands. Ruthenium compounds are considered potential substitutes for known drugs. In particular, Ru(II) and Ru(III) based complexes have reduced toxicity and can be tolerated in vivo. In addition, a wide spectrum of ruthenium oxidation states, a different mechanism of action and the kinetics of ligand substitution increase the advantage over coordination complex compounds based on platinum. In conclusion, in this review, we will focus on the latest reports from the literature on the catalytic properties and biomedical activity of ruthenium(II) and ruthenium(III) chemical compounds.